{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T13:06:35Z","timestamp":1781010395520,"version":"3.54.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40123-026-01367-4","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T01:35:53Z","timestamp":1776389753000},"page":"1941-1954","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Benefit of Latanoprostene Bunod (Vyzulta) for Glaucoma Switched from Prior Pharmacotherapy: A Retrospective Cohort Study in Taiwan"],"prefix":"10.1007","volume":"15","author":[{"given":"Chen-Jui","family":"Chiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Shan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"2","key":"1367_CR1","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1016\/S2214-109X(20)30489-7","volume":"9","author":"GBD 2019 Blindness and Vision Impairment Collaborators VLEGotGBoDS","year":"2021","unstructured":"GBD 2019 Blindness and Vision Impairment Collaborators VLEGotGBoDS. Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2021;9(2):e144\u201360.","journal-title":"Lancet Glob Health"},{"issue":"11","key":"1367_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081\u201390.","journal-title":"Ophthalmology"},{"issue":"3","key":"1367_CR3","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1111\/aos.13568","volume":"96","author":"F Li","year":"2018","unstructured":"Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96(3):e277\u201384.","journal-title":"Acta Ophthalmol"},{"issue":"6","key":"1367_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/17469899.2023.2275587","volume":"18","author":"J-C Wong","year":"2023","unstructured":"Wong J-C, Neustein RF, Ustaoglu M, Shiuey E, Mehran N, Moster MR, et\u00a0al. The long-term clinical outcomes of latanoprostene bunod 0.024% in glaucoma treatment at a tertiary glaucoma center. Expert Rev Ophthalmol. 2023;18(6):421\u20137.","journal-title":"Expert Rev Ophthalmol."},{"issue":"4","key":"1367_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1089\/jop.2018.0134","volume":"35","author":"C Wolfram","year":"2019","unstructured":"Wolfram C, Stahlberg E, Pfeiffer N. Patient-reported nonadherence with glaucoma therapy. J Ocul Pharmacol Ther. 2019;35(4):223\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"6","key":"1367_CR6","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1136\/bjophthalmol-2014-305908","volume":"99","author":"RN Weinreb","year":"2015","unstructured":"Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL. A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99(6):738\u201345.","journal-title":"Br J Ophthalmol"},{"issue":"1-2","key":"1367_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1089\/jop.2016.0188","volume":"34","author":"ME Cavet","year":"2018","unstructured":"Cavet ME, DeCory HH. The role of nitric oxide in the intraocular pressure lowering efficacy of latanoprostene bunod: review of nonclinical studies. J Ocul Pharmacol Ther. 2018;34(1\u20132):52\u201360.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"1367_CR8","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ophtha.2016.01.019","volume":"123","author":"RN Weinreb","year":"2016","unstructured":"Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123(5):965\u201373.","journal-title":"Ophthalmology"},{"issue":"9","key":"1367_CR9","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/IJG.0000000000001904","volume":"30","author":"JE Radell","year":"2021","unstructured":"Radell JE, Sharma HK, Auyeung KL, Paul ME, Gagliuso DJ, Chadha N, et\u00a0al. Two-year experience with latanoprostene bunod in clinical practice. J Glaucoma. 2021;30(9):776\u201380.","journal-title":"J Glaucoma"},{"issue":"11","key":"1367_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s12325-015-0260-y","volume":"32","author":"M Araie","year":"2015","unstructured":"Araie M, Sforzolini BS, Vittitow J, Weinreb RN. Evaluation of the effect of latanoprostene bunod ophthalmic solution, 0.024% in lowering intraocular pressure over 24 h in healthy Japanese subjects. Adv Ther. 2015;32(11):1128\u201339.","journal-title":"Adv Ther"},{"issue":"3","key":"1367_CR11","first-page":"166","volume":"16","author":"B Zhou","year":"2022","unstructured":"Zhou B, Bekerman VP, Khouri AS. Use of latanoprostene bunod as adjunctive glaucoma therapy in refractory glaucoma. J Curr Glaucoma Pract. 2022;16(3):166\u20139.","journal-title":"J Curr Glaucoma Pract"},{"issue":"1","key":"1367_CR12","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/1120672121998913","volume":"32","author":"AA Mehta","year":"2022","unstructured":"Mehta AA, Kanu LN, Sood-Mendiratta S, Quinones R, Hawkins A, Lehrer RA, et\u00a0al. Experience with netarsudil 0.02% and latanoprostene bunod 0.024% as adjunctive therapy for glaucoma. Eur J Ophthalmol. 2022;32(1):322\u20136.","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"1367_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/14656566.2017.1293654","volume":"18","author":"PL Kaufman","year":"2017","unstructured":"Kaufman PL. Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opin Pharmacother. 2017;18(4):433\u201344.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1367_CR14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s40123-020-00307-0","volume":"9","author":"CO Okeke","year":"2020","unstructured":"Okeke CO, Burstein ES, Trubnik V, Deom JE, Cooper MS, Brinkley DA, et\u00a0al. Retrospective chart review on real-world use of latanoprostene bunod 0.024% in treatment-na\u00efve patients with open-angle glaucoma. Ophthalmol Ther. 2020;9(4):1041\u201353.","journal-title":"Ophthalmol Ther"},{"key":"1367_CR15","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/OPTH.S442940","volume":"18","author":"CO Okeke","year":"2024","unstructured":"Okeke CO, Cothran NL, Brinkley DA, Rahmatnejad K, Rodi\u00f1o FJ, Deom JE. Latanoprostene bunod 0.024% in patients with open-angle glaucoma switched from prior pharmacotherapy: a retrospective chart review. Clin Ophthalmol (Auckland, NZ). 2024;18:409\u201322.","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"1367_CR16","doi-asserted-by":"crossref","unstructured":"Kim SH, Song JE, Hwang HS, Lee EJ, Kim T-W, Kim JM. Different intraocular pressure-lowering effects of latanoprostene bunod across glaucoma subtypes: a 12-month real-world clinical study. Graefe\u2019s Arch Clin Exp Ophthalmol. 2025.","DOI":"10.1007\/s00417-025-07085-0"},{"key":"1367_CR17","doi-asserted-by":"publisher","first-page":"1554777","DOI":"10.3389\/fopht.2025.1554777","volume":"5","author":"WD Stamer","year":"2025","unstructured":"Stamer WD, Chiu T, Lu D-W, Wang TH, Rojanapongpun P, Ruangvaravate N, et\u00a0al. Real-world impact of latanoprostene bunod ophthalmic solution 0.024% in glaucoma therapy: a narrative review. Front Ophthalmol. 2025;5:1554777.","journal-title":"Front Ophthalmol."},{"issue":"9","key":"1367_CR18","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1007\/s12325-016-0385-7","volume":"33","author":"K Kawase","year":"2016","unstructured":"Kawase K, Vittitow JL, Weinreb RN, Araie M. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33(9):1612\u201327.","journal-title":"Adv Ther"},{"issue":"1","key":"1367_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/IJG.0000000000000831","volume":"27","author":"RN Weinreb","year":"2018","unstructured":"Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. 2018;27(1):7\u201315.","journal-title":"J Glaucoma"},{"key":"1367_CR20","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ajo.2016.05.012","volume":"168","author":"FA Medeiros","year":"2016","unstructured":"Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250\u20139.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1367_CR21","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/bjophthalmol-2020-317262","volume":"106","author":"P Harasymowycz","year":"2022","unstructured":"Harasymowycz P, Royer C, Cui AX, Barbeau M, Jobin-Gervais K, Mathurin K, et\u00a0al. Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis. Br J Ophthalmol. 2022;106(5):640\u20137.","journal-title":"Br J Ophthalmol"},{"key":"1367_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2023.109444","volume":"232","author":"NA Sharif","year":"2023","unstructured":"Sharif NA. Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness. Exp Eye Res. 2023;232:109444.","journal-title":"Exp Eye Res"},{"key":"1367_CR23","doi-asserted-by":"crossref","unstructured":"Rojanapongpun P, Tantisevi V. Medical therapy in angle closure glaucoma. In: Primary angle closure glaucoma (PACG): a logical approach in management. Springer; 2020. p. 31\u201344.","DOI":"10.1007\/978-981-15-8120-5_4"},{"key":"1367_CR24","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2147\/OPTH.S63760","volume":"8","author":"JK Schmier","year":"2014","unstructured":"Schmier JK, Hulme-Lowe CK, Covert DW. Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. Clin Ophthalmol (Auckland, NZ). 2014;8:1097\u2013104.","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"1367_CR25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2147\/OPTH.S13884","volume":"4","author":"JK Schmier","year":"2010","unstructured":"Schmier JK, Lau EC, Covert DW. Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. Clin Ophthalmol (Auckland, NZ). 2010;4:1137\u201343.","journal-title":"Clin Ophthalmol (Auckland, NZ)"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01367-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01367-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01367-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:27:13Z","timestamp":1781008033000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01367-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1367"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01367-4","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chen-Jui Chiu has nothing to disclose. Yi-Shan Chen has nothing to disclose. Ying-Ying Chen has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Institutional Review Board (IRB) of Kaohsiung Veterans General Hospital (IRB No.: KSVGH25-CT9-01). The study was conducted in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments. Owing to the retrospective design of the study and the use of de-identified clinical data, the requirement for obtaining written informed consent was waived by the IRB in accordance with institutional and national legislation, and patient consent for publication was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}